Story
Neonc Technologies Stock Surges on Positive Brain Cancer Drug Data

Neonc Technologies Holdings Inc. (NTHI) shares surged in pre-market trading after the company announced that its experimental brain cancer therapy, NEO100, met the primary goal in a mid-stage clinical trial. The positive results were amplified by a combination of technical market factors, including a high level of short interest in the stock.
Trial Meets Primary Endpoint
The company disclosed that its Phase 2a NEO100-01 study of intranasal NEO100 for patients with recurrent or progressive Grade III and IV IDH1-mutant glioma achieved its primary endpoint. The trial demonstrated a six-month progression-free survival rate of 48.9%, significantly outperforming a pre-specified benchmark of 20%.
According to the announcement, the result was statistically significant with a p-value of 0.0047. The open-label trial enrolled 24 patients who had previously not responded to standard therapies. Neonc management discussed the efficacy and safety data during an investor call.
Market Factors Amplify Gains
Several factors contributed to the stock's outsized reaction. Heading into the data release, NTHI shares were trading near their 52-week low, creating a low base for a potential rebound. Additionally, a relatively small number of freely traded shares (a tight float) and more than 500,000 shares reported as short created conditions for a potential short squeeze, where traders betting against the stock are forced to buy shares to cover their positions.
Confidence from within the company also appeared high ahead of the announcement. Filings show CEO Amir Heshmatpour made substantial open-market purchases, with total insider buying approaching $1 million over the past year. A positive broader market sentiment provided a supportive backdrop for the rally.
AdRegulatory and Development Outlook
The successful trial outcome is a significant step for NEO100's development path. The drug has already received several important designations from the U.S. Food and Drug Administration (FDA) that could accelerate its journey to market.
These designations include:
- Orphan Drug
- Fast Track
- Rare Pediatric Disease
Combined with the positive Phase 2a data, these regulatory statuses strengthen the asset's profile as the company plans its next steps toward later-stage development.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.